96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

Antiviral Therapy

Volumn 18, Issue 7, 2013, Pages 905-913

  Moyle, Graeme J ^a   Stellbrink, Hans Jürgen ^b   Compston, Juliet ^c   Orkin, Chloe ^d   Arribas, José R ^e   Domingo, Pere ^f   Granier, Catherine ^g   Pearce, Helen ^g   Sedani, Sangeeta ^g   Gartland, Martin ^h  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b Infektionsmedizinisches Centrum Hamburg   (Germany)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g GLAXOSMITHKLINE   (United Kingdom)

^h VIIV HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; BETA 2 MICROGLOBULIN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL BINDING PROTEIN; TRIACYLGLYCEROL;

ADULT; ANGINA PECTORIS; ARTICLE; BONE MINERAL; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOCALCEMIA; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE PROLAPSE; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; THROMBOSIS; TUBULAR DYSFUNCTION; UNSPECIFIED SIDE EFFECT;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; BONE AND BONES; BONE DENSITY; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY; LAMIVUDINE; MALE; ORGANOPHOSPHONATES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892709363     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2667     Document Type: Article

References (33)

1. European AIDS Clinical Society. European AIDS Clinical Society (EACS) Guidelines. Version 6.0 - October 2011. (Accessed 15 May 2012.) Available from http://www.eacsociety.org/Portals/0/iles/pdf%20iles/EACSGuidelines-v6.0-English. pdf
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-333.
3. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23:1603-1614.
4. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-579.
5. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-1426.
6. Kim C, Gupta SK, Green L, et al. Abacavir, didanosine and tenofovir do not induce inlammatory, apoptotic or oxidative stress genes in coronary endothelial cells. Antivir Ther 2011;16:1335-1339.
7. Ding X, Andraca-Carrera E, Cooper C, et al. No association of myocardial infarction with abacavir use: indings of an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract O-1004.
8. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011;25:1993-2004.
9. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Deic Syndr 2009;51:20-28.
10. Gallant JE, De Jesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
11. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and eficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007;8:164-172.
12. Gallant JE, Staszewski S, Pozniak AL, et al. Eficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
13. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Deic Syndr 2008;47:74-78.
14. Viread (tenofovir disoproxil fumarate). Package insert 2012. Gilead Sciences, Inc., Foster City, CA, USA.
15. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a irst case report. Am J Kidney Dis 2002;40:1331-1333.
16. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeiciency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-1073.
17. Créput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17:935-937.
18. Calza L, Trapani F, Tedeschi S, et al. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients. Scand J Infect Dis 2011;43:656-660.
19. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Deic Syndr 2010;53:62-69.
20. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009;27:817-824.
21. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J. Bone mineral density changes in protease inhibitor-sparing vs nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011;12:157-165.
22. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarateemtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011;203:1791-1801.
23. Van Vonderen MG, Lips P, Van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009;23:1367-1376.
24. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012;26:825-831.
25. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeiciency virus (HIV) - infected versus non-HIV-infected patients in a large US healthcare system. J Clin Endocrinol Metab 2008;93:3499-3504.
26. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS ONE 2011;6:e17217.
27. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, eficacy, and safety with oncedaily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Deic Syndr 2010;55:49-57.
28. Stellbrink H-J, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavirlamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963-972.
29. Bernard AM, Vyskocil AA, Mahieu P, Lauwerys RR. Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin Chem 1987;33:775-779.
30. Chitra P, Bakthavatsalam B, Palvannan T. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeiciency virus infected patients on highly active antiretroviral therapy. Clin Chim Acta 2011;412:1151-1154.
31. McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th Conference on Retroviruses and Opportunistic Infections 16-19 February 2010, San Francisco, CA, USA. Abstract 106LB.
32. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361:2230-2240.
33. Smith K Y, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23:1547-1556.